Evaluate the Efficacy and Safety of DWJ108J
NCT06025409
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
79
Enrollment
INDUSTRY
Sponsor class
Conditions
Central Precocious Puberty
Interventions
DRUG:
Leuprolide Acetate 11.25 MG/ML
Sponsor
Daewoong Pharmaceutical Co. LTD.